Martin Mackay
President, PharmaTherapeutics Research & Development

Martin Mackay is the President of Pfizer PharmaTherapeutics Research & Development. He oversees an international network of scientists and other pharmaceutical R&D professionals in Research, Development Operations, Pharmaceutical Sciences, Drug Safety and their functional lines. The Pfizer PharmaTherapeutics organization is advancing a research portfolio of investigational medicines in the following areas: Allergy & Respiratory, Antibacterials, Antivirals, Cardiovascular & Metabolic Diseases, Genitourinary, Neuroscience, Oncology, Pain, Indications Discovery and Regenerative Medicine.

Mackay began his career at Pfizer in 1995 as the Director of Discovery Biology in the U.K. In 1997 he became the Senior Director, Head of Biology, and in 1998, Vice President, U.K. Discovery. He was promoted to Senior Vice President, Head of Worldwide Discovery in 1999 and moved to the United States. In 2003, Mackay was appointed as Head of Worldwide Research and Technology. Early in 2007 he was named Head of Worldwide Development. He was appointed President of Pfizer Global Research and Development in September 2007, and subsequently President of PharmaTherapeutics R&D in 2009.

Prior to joining Pfizer, Mackay earned a Microbiology First Class Honors Degree at Heriot-Watt University and a Ph.D. in Molecular Genetics at the University of Edinburgh in 1983. Between degrees he worked in Antibacterial Discovery at Beecham Pharmaceuticals in Surrey, U.K. Mackay conducted his postdoctoral research fellowship working on malarial vaccines with Professor John Scaife at the University of Edinburgh and Professor Uli Certa at Hoffmann-La Roche Pharmaceuticals in Basel, Switzerland. Mackay joined the Advanced Drug Delivery Research Unit at Ciba-Geigy in Sussex, U.K. and became the Head of Drug Preformulation and Delivery. In 1993, he moved to Ciba's headquarters in Basel, Switzerland as Head of Molecular and Cell Biology, CNS Research, where he led an international team of researchers until his move to Pfizer in 1995.

Mackay is a board member of ViiV Healthcare, the global specialist HIV company established by GlaxoSmithKline and Pfizer. He serves on the Scientific and Regulatory Committee of the industry trade group PhRMA and co-chairs the U.S.-India BioPharma & Healthcare Summit Advisory Board. Mackay was the 2009 recipient of the Genome Valley Excellence Award. He is a member of the Armonk Group, a collaboration of business and academic leaders promoting scientific and technology advancement and economic development in New York State.